ArticleAntibiotics (Basel, Switzerland)2025
Antimicrobial Resistance in ESKAPE Pathogens: A Retrospective Epidemiological Study at the University Hospital of Palermo, Italy.
Article in Antibiotics (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Oxford Nanopore Sequencing, a Promising Technology for Precision Diagnostics in Intensive Care Units: A Narrative Review.Biomedicines · 2026Review
- Plant-Derived Compounds as Antibiotic Adjuvants Against Drug-Resistant ESKAPE Pathogens: Mechanisms of Action, Synergistic Strategies, and Translational Challenges.Antibiotics (Basel, Switzerland) · 2026Review
- Fosfomycin as an adjunctive agent against carbapenem-resistant Acinetobacter baumannii: an updated narrative review.Infection · 2026Review
- Diversity and distinctive characteristics of the global RNA virome in urban and peri-urban environments.Nature communications · 2026Article
- Antimicrobial resistance profiles of ESKAPE pathogens isolated in a microbiology laboratory in Somalia: a two-year retrospective study.BMC infectious diseases · 2026Article
- Comparative Genomic and Functional Characterization ofInternational journal of molecular sciences · 2026Article
- Analysis of Antibiotic Consumption Trends and Pathogens' Epidemiological Profile Within a Multidisciplinary Clinical Hospital from Romania.Antibiotics (Basel, Switzerland) · 2026Article
- Evolution and rise of antimicrobial resistance in key public health bacteria within and across the One Health sectors.Future microbiology · 2026Review
- ESKAPE pathogens and their antimicrobial resistance patterns at the university teaching hospital of Kigali, Rwanda: a five -year analysis (2020-2024).Frontiers in public health · 2026Article
- Phage therapy againstFrontiers in microbiology · 2026Review
- Impact of the Arrangement Modes of the Antimicrobial Motifs WWR-7 and its Analogs in CAMPs on Their Therapeutic Properties.Chemistry, an Asian journal · 2026Article
- Scorpion Venom-Derived Peptides: A New Weapon Against Carbapenem-ResistantMicroorganisms · 2025Article
- Evaluation of EUCAST Rapid Antimicrobial Susceptibility Testing for Gram-Negative ESKAPEEc Pathogens in Blood Cultures, with a Focus on Carbapenemase-ProducingAntibiotics (Basel, Switzerland) · 2025Article
- Five-year surveillance of antimicrobial resistance patterns among blood culture isolates at the University Teaching Hospital, Kigali, Rwanda.Annals of clinical microbiology and antimicrobials · 2025Article
- Antibiotic Resistance Patterns of Bacteria Involved in Colonization and/or Infection of Patients in Intensive Care Units in Northeastern Romania.Antibiotics (Basel, Switzerland) · 2025Article
- Imipenem/Relebactam Plus Aztreonam: First Reported Use in MDRAntibiotics (Basel, Switzerland) · 2025Article
- ESKAPE Pathogens in Bloodstream Infections: Dynamics of Antimicrobial Resistance from 2018 to 2024-A Single-Center Observational Study in Poland.Journal of clinical medicine · 2025Article
- Outcome of Bloodstream Infections Caused by Antibiotic-Resistant Bacteria: A 7-Year Retrospective Study at the University Hospital of Palermo, Italy.Antibiotics (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAntimicrobial resistance (AMR) is an escalating global health threat, projected to cause over 40 million deaths by 2050. ESKAPE pathogens (
methodsMicrobiological data from all specimen types were collected using the Business Intelligence system Biwer, excluding duplicates. We assessed the prevalence and trends of ESKAPE isolates and AMR over time. Clinical data from hospital discharge forms were used to evaluate factors associated with mortality in patients with ESKAPE-positive blood cultures. Differences in AMR prevalence between blood and non-blood isolates were examined.
resultsA total of 11,607 specimens from 4916 patients were analyzed. Most patients were admitted to Internal Medicine (19.4%), the ICU (13.2%), and General Surgery (9.9%). Additionally, 21.5% of the specimens were collected from ICU-admitted patients. Blood cultures accounted for 14.3% of the specimens, urine for 25.3%, respiratory secretions for 22.1%, and skin and mucosal swabs for 20.9%. The prevalence of all isolates increased progressively, peaking in 2021. The vancomycin-resistant
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.